Navigation Links
Patients Often Kept in Dark About 'Off-Label' Drug Use: Study
Date:8/8/2012

WEDNESDAY, Aug. 8 (HealthDay News) -- Many patients who are being treated with "off-label" drugs are unaware that the medications they have been prescribed by their doctor aren't being used in ways that would meet U.S. Food and Drug Administration approval, research shows.

Off-label drug use is a term used to describe when a medication is prescribed using a dosage, form of dosage, or for a purpose that hasn't yet been approved by the FDA, the researchers explained in the report published online Aug. 6 in the Mayo Clinic Proceedings.

"Since the U.S. Food and Drug Administration does not regulate the practice of medicine, off-label drug use has become very common," study lead author Dr. Christopher Wittich, an internal medicine physician at the Mayo Clinic in Rochester, Minn., said in a clinic news release. "Health care providers and patients should educate themselves about off-label drugs to weigh the risks and benefits before a physician prescribes one or a patient takes one."

A 2006 report revealed that among the most common medications, roughly one in five prescriptions was for an off-label use, the researchers pointed out. For example, some antidepressants are considered a primary treatment for neuropathic pain, although this use is not FDA-approved.

Morphine, as well as many inhaled bronchodilators, antimicrobials, anticonvulsants and proton pump inhibitors are also prescribed for children without being FDA-approved for use in kids. Previous research has shown that about 79 percent of kids were taking at least one off-label medication when they were discharged from a children's hospital, the study authors noted in the release.

Because doctors are not required to disclose the off-label use of a drug, and are also not liable for off-label drug use, patients are commonly not told that they are taking a drug in a way that is not FDA-approved, the researchers pointed out.

Drug makers, however, are not allowed to promote off-label uses of their drugs. Doing so can result in hefty fines, the study authors explained. For example, GlaxoSmithKline recently agreed to pay a record $3 billion to settle a case involving alleged off-label drug-use marketing, and Merck Sharp & Dohme was fined $322 million for allegedly promoting the painkiller Vioxx for an off-label use.

But, Wittich and colleagues noted, drug companies are allowed to respond to questions from health care providers and distribute peer-reviewed publications about off-label drug use.

The high costs and lengthy process of obtaining FDA approval may deter drug companies from seeking approval for a new drug indication, the researchers suggested.

More information

The American Cancer Society has more about off-label drug use.

-- Mary Elizabeth Dallas

SOURCE: Mayo Clinic, news release, Aug. 6, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Underinsured Heart Disease Patients Die Sooner, Study Finds
2. Doctors often dont disclose all possible risks to patients before treatment
3. Patients want more risks disclosed before treatment
4. No difference in death rates among patients exposed to common rheumatoid arthritis drugs
5. Weekends More Fatal for Older Patients With Head Injury: Study
6. Coach could be key in helping stroke patients
7. Minority Patients at Higher Risk of Having Ambulances Diverted
8. Tourette Patients Benefit From Behavioral Therapy: Study
9. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
10. Off-label drug use common, but patients may not know theyre taking them, Mayo finds
11. Trauma Patients at Higher Risk of Dying of Hypothermia: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Patients Often Kept in Dark About 'Off-Label' Drug Use: Study
(Date:1/24/2017)... ... January 24, 2017 , ... “Mysteries Revealed On Speaking In ... mysterious phenomenon is available to all Christians. “Mysteries Revealed On Speaking In Tongues” is ... Beautiful Creation,” a Christian-based talk show located in Michigan. , “We need to ...
(Date:1/24/2017)... PA (PRWEB) , ... January 24, 2017 , ... ... breast implants, a new scientific article suggests that autologous fat grafting—taking ... for achieving larger breasts naturally, without breast implants. , Cosmetic Surgeon and ...
(Date:1/24/2017)... IL (PRWEB) , ... January 23, 2017 , ... ... is partnering with Plug and Play, the world’s largest start-up platform headquartered in ... companies a year. , OSF Ventures recently signed a three-year agreement to ...
(Date:1/24/2017)... Texas (PRWEB) , ... January 23, 2017 , ... ... its presence in Texas with the acquisitions of two personal care service companies: ... in Texas City, Texas, effective January 1, 2017. , Well regarded in their ...
(Date:1/24/2017)... ... January 23, 2017 , ... Somnoware, ... plugin that allows sleep centers to automatically connect and initialize all their devices ... client browser plugin is quickly installed on first use and then monitors device ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017  Allergan plc, (NYSE: ... continued support of the International Headache Academy (IHA). Designed to ... and research scientists, IHA offers a three-day, intensive overview on ... Allergan has been the sole sponsor since the inception of ... and iHEAD in Europe in 2014. ...
(Date:1/23/2017)... 23, 2017 Ahead of today,s trading session, ... they have fared at the close: Kite Pharma Inc. (NASDAQ: ... OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... relative laggards on Friday, January 20 th , 2017, down on ... reports on these stocks now at: ...
(Date:1/23/2017)... SAN DIEGO , 23 janvier 2017  ResMed ... Winter Haven , Floride) ont annoncé aujourd,hui qu,ils se ... les litiges existants entre les parties. BMC et 3B ... de paiements de droits à ResMed, et ResMed effectuera ... à 3B pour clore le litige de Floride entre ...
Breaking Medicine Technology: